。Company announced positive results from its Phase 3 clinical trial, THWART-2 (WART-302), of A-101 45% Topical Solution (A-101 45% Topical Solution), an investigational new drug for the treatment of common warts (verruca vulgaris). A-101 45% Topical Solution met the primary and all secondary efficacy endpoints, achieving clinically and statistically significant clearance of common warts. A-101 45% Topical Solution is a proprietary high-concentration hydrogen peroxide topical solution being developed as a potential prescription treatment for common warts. If approved, A-101 45% Topical Solution would be the first FDA approved prescription treatment for common warts. An estimated 22 million Americans each year have common warts problems.
。In July company says that its Phase 2 trial of ATI-501 oral in patients with Alopecia Areata met its primary endpoint. The treatment reached statistically significant improvement over placebo on several hair growth measures.
。Today's stock is up over 80% and trading volume is 22 times average volume, a show of tremendous upside momentum.
。Bullish 3-month Island Reversal Up Pattern, broke above 20 and 50 day moving averages, trend is up. Next resistance is 3, may fill gap to 4.32 if break above 3.
。4 analysts rate stock at Strong Buy and 2 Buy, no Sell. Average price target 3.83. 52 week price range 0.74 to 16.07.
。Book Value 3.32， Cash Per Share 2.66.
Aclaris Therapeutics，Inc。（ACRS）是一家生物制药公司，专注于识别，开发和商业化美国皮肤病和免疫炎症疾病的各种疗法。
。昨日公司宣布其第3期临床试验THWART-2（WART-302），A-101 45％局部用药（A-101 45％局部用药），一种用于治疗常见疣（ verruca vulgaris）的研究性新药有阳性结果。 A-101 45％外用溶液符合主要和所有次要疗效终点，实现临床和统计学上显着的清除常见疣。 A-101 45％外用溶液是一种专利的高浓度过氧化氢外用溶液，正在开发作为常见疣的潜在处方药。如果获得批准，A-101 45％外用溶液将成为FDA首个被批准的常见疣处方药。估计每年有2200万美国人患有常见的疣。
。7月份公司表示其ATI-501斑秃（Alopecia Areata）患者口服ATI-501的2期试验符合其主要终点。 该公司表示，该治疗在几项头发生长方面均优于安慰剂（Placebo）。
。今日股价上涨超过80％，成交量是平均成交量的22倍，表现出巨大的上涨势头。
。看涨的 3个月的岛形反转上行模式并且突破了20日和50日移动均线，趋势上升。下一阻力为3，如果突破3以上可填补缺口至4.32。
。4位分析师评级为强买入和2位买入，无卖出的股票评级。综合目标价3.83。 52周价格区间为0.74至16.07。
。账面价值3.32，每股现金2.66。
No comments:
Post a Comment